Global benchmarks for minimally invasive right hemicolectomy for cancer - Scorecard - MDSpire

Global benchmarks for minimally invasive right hemicolectomy for cancer

  • By

  • Fariba Abbassi

  • Michaela Ramser

  • Matthias Pfister

  • Roxane D Staiger

  • Sun J Kim

  • Ji W Park

  • Bart C T van de Laar

  • Marcos Gonzalez

  • Vittoria Perano

  • Georgette Camilleri

  • David Merino

  • Justin Dourado

  • Anjelli Wignakumar

  • Kohei Shigeta

  • Tomás Mansur Duarte de Miranda Marques

  • Daniel Leonard

  • Kai-Yin Lee

  • Avanish Saklani

  • Kilian G M Brown

  • Fabio Butti

  • Ivana Raguz

  • Carlo Alberto Schena

  • Daichi Kitaguchi

  • Desmond C Winter

  • Masaaki Ito

  • Nicola de’Angelis

  • Dieter Hahnloser

  • Jennifer Vu

  • Ashwin Desouza

  • Bei-En Siew

  • Ker-Kan Tan

  • Alex Kartheuser

  • Samuel Aguiar

  • Koji Okabayashi

  • Carl J Brown

  • Steven Wexner

  • Sebastiano Biondo

  • Danilo Miskovic

  • Antonino Spinelli

  • Carlos A Vaccaro

  • Esther C J Consten

  • Byung S Min

  • Milo A Puhan

  • Matthias Turina

  • December 16, 2025

  • 0 min

Share

Clinical Scorecard: International Standards for Minimally Invasive Right Hemicolectomy in Cancer Treatment

At a Glance

CategoryDetail
ConditionRight-sided colon adenocarcinoma
Key MechanismsComplete mesocolic excision (CME) and central (D3) lymphadenectomy via minimally invasive techniques (laparoscopy or robotic surgery)
Target PopulationAdult patients (≥18 years) with adenocarcinoma of the cecum or ascending colon undergoing elective minimally invasive right hemicolectomy
Care SettingSpecialist colorectal centers with high surgical volume and multidisciplinary tumor boards

Key Highlights

  • Right hemicolectomy quality is improved by meticulous dissection achieving CME and D3 lymphadenectomy.
  • Benchmarking uses ideal low-risk patients from high-volume centers to establish best achievable surgical outcomes.
  • No prior international benchmark cut-offs existed for minimally invasive right hemicolectomy; this study establishes them for 19 key outcome parameters.

Guideline-Based Recommendations

Diagnosis

  • Confirm adenocarcinoma location in right hemicolon (cecum or ascending colon).
  • Exclude other pathologies and synchronous colorectal cancers requiring additional resections.

Management

  • Perform elective minimally invasive right hemicolectomy (laparoscopic or robotic) following oncological principles including CME and D3 lymphadenectomy.
  • Centralize surgery in high-volume colorectal specialist centers with multidisciplinary tumor boards.

Monitoring & Follow-up

  • Collect prospective data on perioperative, oncological, and complication outcomes.
  • Assess morbidity and mortality at hospital discharge, 3 months, and 6 months postoperatively using Clavien–Dindo classification and Comprehensive Complication Index®.
  • Benchmark outcomes against established cut-offs derived from ideal patient cohorts.

Risks

  • Higher complication risk in non-ideal patients with established risk factors for postoperative morbidity.
  • Potential quality gaps in low-volume centers or non-specialist surgeons.

Patient & Prescribing Data

Elective minimally invasive right hemicolectomy patients with right-sided colon adenocarcinoma, stratified into ideal (low-risk) and non-ideal (high-risk) groups.

Benchmark cut-offs derived from ideal patients enable identification of quality gaps and guide improvements in surgical outcomes.

Clinical Best Practices

  • Centralize right hemicolectomy procedures in high-volume colorectal specialist centers.
  • Use minimally invasive techniques (laparoscopy or robotic) adhering to oncological principles of CME and D3 lymphadenectomy.
  • Implement continuous prospective data collection and multidisciplinary tumor board discussions.
  • Apply standardized outcome measures including Clavien–Dindo classification and Comprehensive Complication Index® for morbidity assessment.
  • Utilize benchmarking against international cut-offs to monitor and improve surgical quality.

References

Original Source(s)

Global benchmarks for minimally invasive right hemicolectomy for cancer

  • by Fariba Abbassi, Michaela Ramser, Matthias Pfister, Roxane D Staiger, Sun J Kim, Ji W Park, Bart C T van de Laar, Marcos Gonzalez, Vittoria Perano, Georgette Camilleri, David Merino, Justin Dourado, Anjelli Wignakumar, Kohei Shigeta, Tomás Mansur Duarte de Miranda Marques, Daniel Leonard, Kai-Yin Lee, Avanish Saklani, Kilian G M Brown, Fabio Butti, Ivana Raguz, Carlo Alberto Schena, Daichi Kitaguchi, Desmond C Winter, Masaaki Ito, Nicola de’Angelis, Dieter Hahnloser, Jennifer Vu, Ashwin Desouza, Bei-En Siew, Ker-Kan Tan, Alex Kartheuser, Samuel Aguiar, Koji Okabayashi, Carl J Brown, Steven Wexner, Sebastiano Biondo, Danilo Miskovic, Antonino Spinelli, Carlos A Vaccaro, Esther C J Consten, Byung S Min, Milo A Puhan, Matthias Turina

  • December 16, 2025

Related Content

Gender equity and professional experience of female colorectal surgeons in Italy: results of a National survey

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.